{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:16:06Z","timestamp":1778030166469,"version":"3.51.4"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/bor.0000000000000084","type":"journal-article","created":{"date-parts":[[2014,7,11]],"date-time":"2014-07-11T15:20:29Z","timestamp":1405092029000},"page":"528-537","source":"Crossref","is-referenced-by-count":33,"title":["Update on infections and vaccinations in systemic lupus erythematosus and Sj\u00f6gren's syndrome"],"prefix":"10.1097","volume":"26","author":[{"given":"Sandra G.","family":"Pasoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C.M.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloisa","family":"Bonfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-10-20210128","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32833c36c5","article-title":"Pathogenesis of Sjogrens syndrome and therapeutic consequences.","volume":"22","author":"Mariette","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"R3-10-20210128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/BOR.0b013e3283476cd8","article-title":"Infections in the lupus patient: perspectives on prevention.","volume":"23","author":"Barber","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"R4-10-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.berh.2013.07.002","article-title":"Management of infection in systemic lupus erythematosus.","volume":"27","author":"Sciascia","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R5-10-20210128","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3899\/jrheum.100819","article-title":"Multiple oral Candida infections in patients with Sjogrens syndrome: prevalence and clinical and drug susceptibility profiles.","volume":"38","author":"Yan","year":"2011","journal-title":"J Rheumatol"},{"key":"R6-10-20210128","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10067-013-2408-y","article-title":"Tuberculosis infection in primary Sjogrens syndrome: a nationwide population-based study.","volume":"33","author":"Chang","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R7-10-20210128","first-page":"1061","article-title":"Influenza AH1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy Rheumatology (Oxford","volume":"51","author":"Borba","year":"2012","journal-title":")"},{"key":"R8-10-20210128","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.vaccine.2013.01.057","article-title":"Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjogrens syndrome.","volume":"31","author":"Pasoto","year":"2013","journal-title":"Vaccine"},{"key":"R10-10-20210128","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1084\/jem.20081761","article-title":"Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from toll-like receptor 3.","volume":"206","author":"Iwakiri","year":"2009","journal-title":"J Exp Med"},{"key":"R11-10-20210128","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.4049\/jimmunol.1101575","article-title":"Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjogrens syndrome.","volume":"188","author":"Inoue","year":"2012","journal-title":"J Immunol"},{"key":"R12-10-20210128","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autrev.2013.09.004","article-title":"The cryptic interplay between systemic lupus erythematosus and infections.","volume":"13","author":"Rigante","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R13-10-20210128","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/BOR.0b013e32836200d2","article-title":"Autoimmunity and infection in Sjogrens syndrome.","volume":"25","author":"Igoe","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"R14-10-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/2049-632X.12066","article-title":"Peptide matching between Epstein-Barr virus and human proteins.","volume":"69","author":"Capone","year":"2013","journal-title":"Pathog Dis"},{"key":"R15-10-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/BOR.0b013e3283535801","article-title":"Lupus and Epstein-Barr.","volume":"24","author":"James","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"R17-10-20210128","first-page":"1149","article-title":"EBV reactivation serological profile in primary Sjogrens syndrome: an underlying trigger of active articular involvement Rheumatol I","volume":"33","author":"Pasoto","year":"2013","journal-title":"nt"},{"key":"R18-10-20210128","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2014.02.008","article-title":"Infection and autoimmunity in Sjogrens syndrome: a clinical study and comprehensive review.","volume":"51","author":"Kivity","year":"2014","journal-title":"J Autoimmun"},{"key":"R19-10-20210128","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.archoralbio.2014.02.003","article-title":"IL-1 and TNF- regulation of aryl hydrocarbon receptor (AhR) expression in HSY human salivary cells.","volume":"59","author":"Drozdzik","year":"2014","journal-title":"Arch Oral Biol"},{"key":"R21-10-20210128","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/BOR.0b013e32833c6297","article-title":"Endogenous retroviral pathogenesis in lupus.","volume":"22","author":"Perl","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"R22-10-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/jhg.2013.6","article-title":"DNA methylation of human endogenous retrovirus in systemic lupus erythematosus.","volume":"58","author":"Nakkuntod","year":"2013","journal-title":"J Hum Genet"},{"key":"R23-10-20210128","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1136\/ard.2010.128736","article-title":"Association of human T lymphotropic virus type I with Sjogrens syndrome.","volume":"69","author":"Hida","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R24-10-20210128","first-page":"809","article-title":"Detection of HTLV-1 in the labial salivary glands of patients with Sjogrens syndrome: a distinct clinical subgroup J R","volume":"39","author":"Lee","year":"2012","journal-title":"heumatol"},{"key":"R25-10-20210128","first-page":"869","article-title":"Hepatitis C virus and Sjogrens syndrome: trigger or mimic Rheum Dis Clin North A","volume":"34","author":"Ramos-Casals","year":"2008","journal-title":"m"},{"key":"R26-10-20210128","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","article-title":"Sjogrens International Collaborative Clinical Alliance (SICCA) Research GroupsAmerican College of Rheumatology classification criteria for Sjogrens syndrome: a data-driven, expert consensus approach in the Sjogrens International Collaborative Clinical Alliance cohort.","volume":"64","author":"Shiboski","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R27-10-20210128","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1136\/jcp.2010.080036","article-title":"Xerostomia, hyposalivation and sialadenitis in patients with chronic hepatitis C are not associated with the detection of HCV RNA in saliva or salivary glands.","volume":"63","author":"de Grossmann","year":"2010","journal-title":"J Clin Pathol"},{"key":"R28-10-20210128","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1128\/CVI.00194-12","article-title":"Chronic hepatitis C virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells.","volume":"19","author":"Roughan","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"R29-10-20210128","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1177\/0961203310365715","article-title":"Clinical and molecular evidence for association of SLE with parvovirus B19.","volume":"19","author":"Pavlovic","year":"2010","journal-title":"Lupus"},{"key":"R30-10-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2014.02.004","article-title":"T cell epitope mimicry between Sjogrens syndrome antigen A (SSA)Ro60 and oral, gut, skin and vaginal bacteria.","volume":"152","author":"Szymula","year":"2014","journal-title":"Clin Immunol"},{"key":"R31-10-20210128","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00296-011-1847-5","article-title":"Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan.","volume":"32","author":"Lin","year":"2012","journal-title":"Rheumatol Int"},{"key":"R32-10-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10067-013-2383-3","article-title":"Death causes and pathogens analysis of systemic lupus erythematosus during the past 26 years.","volume":"33","author":"Fei","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R33-10-20210128","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/acr.22173","article-title":"Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies.","volume":"66","author":"Yurkovich","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R34-10-20210128","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.30277","article-title":"Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China.","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R35-10-20210128","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0961203313490240","article-title":"Clinical presentations and outcomes of systemic lupus erythematosus patients with infection admitted to the intensive care unit.","volume":"22","author":"Han","year":"2013","journal-title":"Lupus"},{"key":"R36-10-20210128","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1177\/0961203313493032","article-title":"Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies.","volume":"22","author":"Danza","year":"2013","journal-title":"Lupus"},{"key":"R37-10-20210128","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus.","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R38-10-20210128","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"MAINTAIN Nephritis Trial GroupAzathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R39-10-20210128","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"R40-10-20210128","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Club Rhumatismes et InflammationSafety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry.","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R41-10-20210128","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/ar3397","article-title":"BIOGEAS Study GroupRates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label.","volume":"13","author":"Diaz-Lagares","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"R42-10-20210128","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study.","volume":"21","author":"Fernandez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"R43-10-20210128","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R44-10-20210128","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"BLISS-76 Study GroupA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R45-10-20210128","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"BLISS-52 Study GroupEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"R47-10-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.","volume":"70","author":"Van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R48-10-20210128","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MD.0b013e31818ec711","article-title":"Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature.","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"R49-10-20210128","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3899\/jrheum.111498","article-title":"Invasive fungal infections in patients with systemic lupus erythematosus.","volume":"39","author":"Martinez-Martinez","year":"2012","journal-title":"J Rheumatol"},{"key":"R50-10-20210128","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/0022-3859.68653","article-title":"Systemic lupus erythematosus and tuberculosis: a review of complex interactions of complicated diseases.","volume":"56","author":"Prabu","year":"2010","journal-title":"J Postgrad Med"},{"key":"R51-10-20210128","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1177\/0961203310375269","article-title":"Lupus pleuritis: a relevant risk factor for pulmonary tuberculosis.","volume":"19","author":"Pasoto","year":"2010","journal-title":"Lupus"},{"key":"R52-10-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0961203312470186","article-title":"Increased incidence of herpes zoster among patients with systemic lupus erythematosus.","volume":"22","author":"Chakravarty","year":"2013","journal-title":"Lupus"},{"key":"R53-10-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RHU.0b013e3181d52ed7","article-title":"Incidence, risk factors, and outcome of herpes zoster in systemic lupus erythematosus.","volume":"16","author":"Borba","year":"2010","journal-title":"J Clin Rheumatol"},{"key":"R54-10-20210128","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1590\/S1807-59322011000700009","article-title":"Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort.","volume":"66","author":"Chen","year":"2011","journal-title":"Clinics (Sao Paulo)"},{"key":"R55-10-20210128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10067-010-1606-0","article-title":"Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.","volume":"30","author":"Santana","year":"2011","journal-title":"Clin Rheumatol"},{"key":"R56-10-20210128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3899\/jrheum.111044","article-title":"C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8A9 and procalcitonin.","volume":"39","author":"Kim","year":"2012","journal-title":"J Rheumatol"},{"key":"R57-10-20210128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.autrev.2012.03.009","article-title":"Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.","volume":"12","author":"Sciascia","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R58-10-20210128","first-page":"3252","article-title":"Clinical and prognostic characteristics of 573 cases of primary Sjogrens syndrome.","volume":"123","author":"Lin","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"R59-10-20210128","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and systemic medications for the treatment of primary Sjogrens syndrome.","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"R60-10-20210128","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/art.38429","article-title":"PGRx Lupus Study GroupThe risk of systemic lupus erythematosus associated with vaccines: an international case-control study.","volume":"66","author":"Grimaldi-Bensouda","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R61-10-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1620\/tjem.229.29","article-title":"Influenza vaccination in autoimmune rheumatic disease patients.","volume":"229","author":"Milanovic","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"R62-10-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.molimm.2013.01.012","article-title":"Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis.","volume":"54","author":"Csuka","year":"2013","journal-title":"Mol Immunol"},{"key":"R63-10-20210128","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"key":"R64-10-20210128","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10067-013-2266-7","article-title":"Human papillomavirus vaccine and systemic lupus erythematosus.","volume":"32","author":"Gatto","year":"2013","journal-title":"Clin Rheumatol"},{"key":"R65-10-20210128","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.","volume":"347","author":"Arnheim-Dahlstrom","year":"2013","journal-title":"BMJ"},{"key":"R66-10-20210128","doi-asserted-by":"crossref","first-page":"8279","DOI":"10.1016\/j.vaccine.2011.08.106","article-title":"Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.","volume":"29","author":"Gee","year":"2011","journal-title":"Vaccine"},{"key":"R67-10-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/annrheumdis-2012-201393","article-title":"Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.","volume":"72","author":"Mok","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R68-10-20210128","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes zoster vaccination in SLE: a pilot study of immunogenicity.","volume":"40","author":"Guthridge","year":"2013","journal-title":"J Rheumatol"},{"key":"R69-10-20210128","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.semarthrit.2011.05.004","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.","volume":"41","author":"Vananuvat","year":"2011","journal-title":"Semin Arthritis Rheum"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:32:23Z","timestamp":1620948743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201409000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000084","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}